The UK Medicines and Healthcare products Regulatory Agency (MHRA) has announced plans for involving patients and the public more closely and systematically in regulatory decision-making processes, committees and governance as part of its efforts to become a “patient focused regulator.”
Specific areas where the agency would like to see more public engagement include drug evaluations under the new Innovative Licensing...